ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0347

Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Abstract Number: LB21

IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Abstract Number: 1192

Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Abstract Number: 0858

IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Abstract Number: 0835

IgG Glycome In Early Rheumatoid Arthritis Differs From Matched Controls and Links Less Lean Mass to an Early Aging Phenotype
Abstract Number: 2529

IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features
Abstract Number: 1190

IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort
Abstract Number: 0978

IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
Abstract Number: 1159

IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Abstract Number: 0061

IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Abstract Number: 0979

IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Abstract Number: 0403

IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Abstract Number: 2495

IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
Abstract Number: 1962

Imaging findings in patients with enteropathic spondyloarthritis
Abstract Number: 2610

Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].